American Journal of Biomedicine and Pharmacy
https://biojournals.us/index.php/AJBP
ISSN: 2997-7177

Drugs That Increase the Tone of the Human Body and Pharmacological Characteristics of Immunodeficiency Agents

Sokhib Rashidov Zamon o‘g‘li, Nilufar Ergasheva Ag’zamjon qizi, Elyor Zokirboyev Anvarjon o‘gli, Umidjon Akramov Abdusamad o‘g‘li, Aziza Egamberdieva Farkhod qizi
Department of pharmacology, Tashkent medical academy

Received: 2024, 15, Mar
Accepted: 2025, 21, Apr
Published: 2025, 31, May

Annotation: These days, psychoactive substances—such as cognitive enhancers, which can improve or restore brain function—as well as "recreational" drugs, like novel psychoactive substances (NPS), are still, and in some cases, are becoming, more widely available. There are advantages and disadvantages to using psychoactive drugs. While new medications to treat cognitive symptoms in neuropsychiatric or neurodegenerative disorders may be very helpful for many patient groups, the ease with which recreational NPS is becoming more widely available and the growing prevalence of cognitive enhancers among healthy individuals means that managing psychoactive substances effectively will become more and more important. A class of medications known as immunosuppressants works by preventing or lessening the body's immune response. The majority of these drugs work by making the body less likely to reject an organ transplant. Immunosuppressive drugs are required in solid organ transplantation in order to maintain organ rejection, manage late-stage immunosuppression, or initiate early-stage immunosuppression. This advancement is mostly due to the development of new drugs and advancements in post-transplant immunosuppressive protocols. These medications do, however, also raise the risk of

infection, cancer, and certain negative side effects that are unique to each agent in patients, especially in pregnant women and those who are having fertility problems. The coronavirus disease, a contentious issue, has improved the effectiveness of immunosuppressive medications but still need further research. Many immunosuppressive protocols are used at transplant facilities worldwide; nevertheless, each patient may need a customized immunosuppression regimen to balance the benefits and potential risks of treatment, thereby removing the chance of recurrence of their initial disease.

Keywords: Attention deficit hyperactivity disorder, central nervous system, gamma-Aminobutyric acid, immunosuppression, negative side effects, the body's immune response.

Introduction. For a large portion of recorded history, psychoactive drug usage has been a part of human society. The growing trend of healthy people using drugs to improve their cognitive abilities has garnered both favorable and unfavorable media coverage in recent years. For example, the Care Quality Commission found that, in line with prior years, the UK saw an 8.7% increase in methylphenidate prescriptions in 2015 compared to 2014. They ascribed this rise to the growing number of general practitioners diagnosing attention deficit hyperactivity disorder (ADHD), but crucially, they also pointed to the disorder's potential for abuse and distraction. Similarly, a 2016 poll conducted by The Student Room among 2000 students in the UK found that 10% had previously used medications like modafinil or the peptide nootropic and would do so again [1-4]. Healthy people utilize psychoactive substances for purposes other than improving their cognitive function. The emergence and use of what were once referred to as "legal highs" or novel psychoactive substances (NPS) have increased at an unprecedented rate in recent years, coinciding with the rise in the use of "smart drugs." This review's objective is to compile research on how NPS and cognitive-enhancing drugs affect healthy people. The study also offers research studies analyzing the characteristics and motivations of consumers of these psychoactive substances. Finally, we discuss ethical and societal consequences of the increasing lifestyle use of cognitive-enhancing medications and hazards connected with NPS usage [5-9]. Immunosuppression is defined as a condition of temporary or permanent immune system deficiency resulting from insults to the immune response within increased resistance to disease and the immune system. This dysfunction also arises from inflammation of the immune system cells, due to their compromised activity in a non-specific manner against primary and subsequent pathogens. Immunosuppression is the manifestation of the causative agent's overall replicative approach, leading to increased vulnerability to other pathogens, but not necessarily to the causative factor. Over the past 60 years, human organ transplantation has advanced, saving many lives worldwide. One of the most important processes is organ preservation, which involves immunosuppressive medications or immunosuppressant, which is commonly used in patients to prevent organ rejection by exerting a suppressive effect on the immune system [10-15]. Furthermore, as was previously mentioned, different immunosuppressive drugs have different

sites of action. For these agents the site of action is briefly addressed in. This advancement is mostly due to the development of new drugs and advancements in post-transplant immunosuppressive protocols. However, It also increases the danger of infection, malignancies and other undesirable side effects specific to each medication in patients. Many immunosuppressive protocols are used at transplant facilities worldwide; nevertheless, each patient may need a specially designed immunosuppression regimen to control the benefits and potential side effects of treatment, thereby removing the chance of recurrence of their initial disease [16-20].

The main purpose of this presented analytical manuscript is drugs that increase the tone of the human bod ana the analysis of the pharmacological characteristics of immunodeficiency agents consists in conducting a brief review based on many years of scientific research

Pharmacological improvement of cognitive function in healthy individuals. Drugs with cognitive enhancing potential. Traditional stimulants used to treat ADHD, such as methylphenidate (Ritalin) and amphetamine, which are most commonly prescribed as mixed amphetamine salts that primarily contain dextroamphetamine (Adderall), are popular prescription drugs used for enhancement. Modafinil is a relatively new stimulant used to treat sleep disorders, including narcolepsy, sleep apnea, and shift-work sleep disorder. It is believed that the main way that methylphenidate and Adderall improve attention in ADHD is by raising dopamine and noradrenaline levels in the prefrontal cortex and the cortical and subcortical regions that project to it [5-11]. Along with its major effects on dopamine and noradrenaline, modafinil also modifies histamine, orexin, GABA, glutamate, and 5-HT (serotonin). Glutamate, noradrenaline, and dopamine are thought to be involved in modafinil's cognitive-enhancing and task-related motivational effects. Other medications that are said to improve cognition include β-blockers like propranolol and atomoxetine, a highly selective noradrenaline reuptake inhibitor used to treat ADHD, and acetylcholinesterase inhibitors like donepezil, which are used to treat Alzheimer's disease. Given the interaction between motivation, mood and cognitive performance, people are also using drugs that improve sleep, reduce anxiety (e.g. benzodiazepines) and improve mood (e.g. selective 5-HT reuptake inhibitors) [15-21].

New psychotropic compounds. Classes of medications and prevalence. Many of the NPS that are used are classified as stimulant-type drugs, hallucinogens, cannabis-like compounds, dissociative drugs, sedatives/hypnotics, and opioids, though there are hundreds of them. The bulk of NPS are synthetic cannabinoid receptor agonists, stimulants, and hallucinogens, according to pharmacological studies and seizure data. In Europe, synthetic cannabinoids and synthetic cathinones are the main type of NPS that are monitored and in 2014 accounted for approximately 70% of the total number of seizures. Synthetic cannabinoids, sometimes referred to as "spice," are strong agonists at the CB1 and CB2 cannabinoid receptors and are meant to be used in place of cannabis [1,3,4,5,7]. The second-largest class of NPS under observation are synthetic cathinones, which are stimulants that resemble the effects of cocaine, amphetamine, and MDMA. These medications typically increase the release of dopamine, noradrenaline, and 5-HT monoamines or prevent their re-uptake. Since its initial release in 2008/2009, mephedrone has established itself as a well-known substance in the market and is typically the most widely used synthetic cathinone. Inhaling nitrous oxide for recreational purposes has grown in popularity, especially in the US and the UK. Nitrous oxide, also known as "laughing gas," is now the sixth most popular drug worldwide, according to preliminary results from the 2016 Global Drug Survey, which also shows a rise in its use in the UK [8-12].

Immunosuppressive medications in certain unique situations. Pregnancy and fertility. The degree of immunosuppression usually lessens over time, particularly during the first year post allogeneic organ transplantation. The elimination of sick cells by chemotherapy is commonly followed by allogeneic hematopoietic stem-cell transplantation. Male transplant recipients exhibit dose-dependent decreases in testosterone plasma concentrations, increases in gonadotrophins, and improvements in spermatogenesis in comparison to the general population.

These gonadal alterations prior to organ donation, however, are not as significant. Immunosuppressive medications have been used to treat a variety of illnesses, and as new medications have been developed and their adverse effects have been better understood, immunosuppressive medications have also been used during pregnancy [5-11]. Because of their teratogenic effects, these medications were deemed contraindicated a number of years ago. Although the higher risk of preterm delivery in female transplant patients is frequently attributed to maternal status rather than immunosuppression, steroids are also linked to an increased risk of premature membrane disruption, and cyclosporines are linked to an increased rate of premature births [12,13]. There are differing research findings on methotrexate's detrimental effects on spermatogenesis. If this effect is real, it usually goes away three months after therapy stops. Due to the mutagenic effect, it is advised that males wait three months after stopping treatment before becoming pregnant. There is no proof that it has a teratogenic impact. There is no proof that mycophenolate affects male fertility. Similar to the general population, many births having transplanted dads who had Mycophenolate treatment had a similar prevalence of preterm and abnormalities. Cyclophosphamide kills mammalian embryos and is mutagenic and teratogenic. It is a known teratogenic agent since it causes malformations of the brain and extremities in humans [15-19].

Immunomodulators continue to play a major role in guiding medical practice, providing promising pathways for customized molecular therapies, and having significant promise for the future of healthcare. Their subtle ways of modifying the immune system's responses highlight their indispensable role in treating a variety of health issues, placing them at the forefront of modern medical progress. Immunomodulators, including immunostimulants and immunosuppressants, are crucial in controlling the immune response, strengthening the body's natural defenses against infections, and immunosuppressants are crucial in preventing organ rejection and treating autoimmune diseases. These drug classes include glucocorticoids, cytostatic agents, antibodies, and other compounds, each of which targets a different aspect of the immune system [13-17]. Through complex molecular and cellular mechanisms, immunomodulators shape immune responses, reduce inflammation, and alter immune cell activities by interacting with key molecules like cytokines and signaling pathways. MSCs have become a promising avenue in immunomodulation because of their ability to suppress immune reactions, control inflammatory responses, induce immune tolerance, and promote tissue regeneration. These diverse properties highlight the potential of MSCs in treating immune-related diseases, assisting with organ transplantation, and promoting tissue repair. In clinical applications, immunomodulators have taken a leading role in the treatment of autoimmune diseases, improving cancer immunotherapy, preventing organ rejection in transplant recipients, and preventing organ rejection [18-21].

Discussion. Not only are psychoactive substances still, and in some cases are becoming more, readily available today, but so are "recreational" drugs like novel psychoactive substances (NPS) and treatments for mental health conditions like cognitive enhancers, which can improve or restore brain function. There are advantages and disadvantages to using psychoactive drugs. While new medications to treat cognitive symptoms in neuropsychiatric or neurodegenerative disorders may be very helpful for many patient groups, the effective management of psychoactive substances will become more and more important as recreational NPS becomes more widely available and as healthy individuals use cognitive enhancers more frequently [1-4]. We should keep investing in the development of cognitive enhancers as treatments for neurodegenerative diseases and psychiatric disorders, such as Alzheimer's disease, attention deficit hyperactivity disorder, and schizophrenia, because it is obvious that these drugs have significant and growing potential benefits, especially as the population ages. However, the increasing use of cognitive enhancers by healthy individuals presents safety, ethical and regulatory problems, which should not be overlooked. Similar to this, increased knowledge of the short- and long-term effects of NPS usage, along with a deeper comprehension of user

motivations and profiles, may help to advance more successful harm reduction and prevention initiatives [5,9,10,11]. However, as a community, we must not overlook the detrimental elements—such as stress and mounting demands at work—that may encourage individuals to use these medicines. It will also be vital to evaluate ethical questions of compulsion and justice, safety issues and society values and viewpoints. Healthy people are using a wide range of NPS in addition to medications for cognitive enhancement to improve their creativity, interior exploration, self-medication, and enjoyment. Over the past eight years, NPS use has fundamentally altered the drug landscape, with many drug users now having a strong NPS in their lives. its appeal has been fueled by its previously legal status, decreased cost, and expanded availability over the Internet [3-7]. In the twenty-first century, immunosuppressive drugs are recommended for a number of different illnesses due to their efficacy as well as a better knowledge of their mechanisms of action and adverse effects. For some young individuals who have previously experienced clear-cut life-threatening ailments, parenthood is now an option due to the ease with which underlying illnesses can now be improved. However, these operations continue to be successful medicines that require careful handling; it should be noted that the long-term implications are still poorly understood. When advising and monitoring patients, it is necessary to take into account the recommendations for the use of a very low level of proof [9-12]. Through complex molecular and cellular mechanisms, immunomodulators shape immune responses, reduce inflammation, and alter immune cell activities by interacting with key molecules like cytokines and signaling pathways. MSCs have become a promising avenue in immunomodulation because of their ability to suppress immune reactions, control inflammatory responses, induce immune tolerance, and promote tissue regeneration. These diverse properties highlight the potential of MSCs in treating immune-related diseases, assisting with organ transplantation, and promoting tissue repair. In clinical applications, immunomodulators have taken a key role in the treatment of autoimmune diseases, improving cancer immunotherapy, preventing organ rejection in transplant recipients, and preventing organ rejection [16-21].

Conclusions. Healthy people's growing lifestyle use of various NPS and cognitive-enhancing medications shows that they want to improve their motivation, enjoyment, creativity, and cognitive function. It has been demonstrated that cognitive-enhancing medications can somewhat improve cognitive function in healthy people, and modafinil may be helpful for some groups, including shift workers and doctors who don't get enough sleep. Therefore, more research and consideration should be given to the benefits of well-established smart medications, like modafinil, in healthy individuals. Many people are drawn to cognitive enhancement as a means of improving themselves in a knowledge economy.

Its appeal has been fueled by its previously legal status, decreased cost, and expanded availability over the Internet. However, it is increasingly clear that these drugs may be linked to serious negative health outcomes. It is yet unknown how they may affect mental and physical health in the long run. To better understand these substances' acute and long-term health consequences and to develop effective harm reduction methods, further study is required on these substances and their usage patterns. The use of pharmaceuticals by healthy individuals to improve their motivation, creativity, enjoyment, and cognitive abilities is transforming society as we know it.

Immunosuppressive drugs are recommended for a number of disorders in the twenty-first century due to their efficacy as well as a better knowledge of their mechanisms of action and adverse effects. Because of its efficacy, underlying ailments can now be improved more easily, giving some young individuals who previously had life-threatening conditions an alternative to parenting. Nevertheless, these techniques continue to be successful treatments that require careful management; it should be noted that the long-term consequences are yet unclear. When counseling and monitoring patients, recommendations for the application of a very low standard of evidence must be taken into account.

References.

1. d'Angelo LC, Savulich G, Sahakian BJ. Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure. Br J Pharmacol. 2017 Oct;174(19):3257-3267. doi: 10.1111/bph.13813.
2. Hussain Y, Khan H. Immunosuppressive Drugs. Encyclopedia of Infection and Immunity. 2022:726–40. doi: 10.1016/B978-0-12-818731-9.00068-9.
3. Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015a). The concise guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 172: 5744–5869.
4. Alexander SPH, Peters JA, Kelly E, Marrion N, Benson HE, Faccenda E et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Ligand-gated ion channels. Br J Pharmacol 172: 5870–5903.
5. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015c). The concise guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
6. Brühl AB, Sahakian BJ (2016). Drugs, games, and devices for enhancing cognition: implications for work and society. Ann N Y Acad Sci 1369: 195–217.
7. Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJA, Parsons LH (2016). Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci 17: 293–306.
8. *Adams D.M., et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016;137(2) doi: 10.1542/peds.2015-3257.*
9. *Ahmed A.R., et al. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up. International Immunopharmacology. 2016;34:25–31. doi: 10.1016/j.intimp.2016.02.013.*
10. Akbari M., et al. Topical tacrolimus as an adjunct to conventional therapy for stromal herpetic keratitis: A randomized clinical trial. Journal of Ophthalmic & Vision Research. 2019;14(4):400. doi: 10.18502/jovr.v14i4.5437.
11. *Akioka K., et al. Transplantation Proceedings. Elsevier; 2017. Hyperuricemia and acute renal failure in renal transplant recipients treated with high-dose mizoribine.*
12. Kim J.H., et al. Increased exposure of tacrolimus by co-administered mycophenolate mofetil: Population pharmacokinetic analysis in healthy volunteers. Scientific Reports. 2018;8(1):1–9. doi: 10.1038/s41598-018-20071-3.
13. *Lin R., et al. Population pharmacokinetics of azathioprine active metabolite in patients with inflammatory bowel disease and dosage regimens optimisation. Basic & Clinical Pharmacology & Toxicology. 2021;128(3):482–492. doi: 10.1111/bcpt.13530.*
14. *Mallat S.G., et al. CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor–based regimen versus a CNI-based regimen: A systematic review and meta-analysis of randomized, controlled trials. Clinical Journal of the American Society of Nephrology. 2017;12(8):1321–1336. doi: 10.2215/CJN.13221216.*
15. Sharma, Y., Arora, M. & Bala, K. The potential of immunomodulators in shaping the future of healthcare. *Discov Med* **1**, 37 (2024). https://doi.org/10.1007/s44337-024-00029-3
16. Klawitter J, Nashan B, Christians U. Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf. 2015;14:1055.
17. Han Y, Li X, Zhang Y, Han Y, Chang F, Ding J. Mesenchymal stem cells for regenerative medicine. Cells. 2019;8:886.

18. Planat-Benard V, Varin A, Casteilla L. MSCs and Inflammatory Cells Crosstalk in Regenerative Medicine: Concerted Actions for Optimized Resolution Driven by Energy Metabolism. Front Immunol. 2021;12.
19. Wang M, Yuan Q, Xie L. Mesenchymal stem cell-based immunomodulation: properties and clinical application. Stem Cells Int. 2018. https://doi.org/10.1155/2018/3057624.
20. Gao F, Chiu SM, Motan DAL, Zhang Z, Chen L, Ji HL, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016;7: e2062.
21. Strzelec M, Detka J, Mieszczak P, Sobocińska MK, Majka M. Immunomodulation—a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system. Front Immunol. 2023;14:1127704.